Triple
T33245741
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | infliximab-axxq |
E851093
|
entity |
| Predicate | hasBiosimilarRelationship |
P37220
|
FINISHED |
| Object | highly similar to reference infliximab |
—
|
LITERAL FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: highly similar to reference infliximab | Statement: [infliximab-axxq, hasBiosimilarRelationship, highly similar to reference infliximab]
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: hasBiosimilarRelationship Context triple: [infliximab-axxq, hasBiosimilarRelationship, highly similar to reference infliximab]
-
A.
hasBiosimilar
chosen
Indicates that one biological product is a biosimilar counterpart to another reference biological product.
-
B.
notableBiosimilarArea
Indicates that an entity is significantly involved in, or recognized for, work related to a particular biosimilar product or therapeutic area.
-
C.
hasBispecificity
Indicates that an entity (typically a molecule or antibody) possesses specificity for two distinct targets or binding sites simultaneously.
-
D.
relatedDrug
Indicates that one drug has a specified relationship or association with another drug, such as interaction, similarity, or therapeutic linkage.
-
E.
hasCommonDoseStrength
Indicates that two medicinal products share at least one identical dosage strength.
- F. None of above.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69f34962386c81909ddc3bf9e18ddeb8 |
completed | April 30, 2026, 12:21 p.m. |
| NER | Named-entity recognition | batch_69f74062b9388190b30546cf700a825c |
completed | May 3, 2026, 12:32 p.m. |
| PD | Predicate disambiguation | batch_69f73c802b848190b61a416b7488bd96 |
completed | May 3, 2026, 12:16 p.m. |
Created at: May 1, 2026, 1:31 a.m.